

Updates at a Glance

Additional indications (n=59) incorporated within Immune Globulin Utilization Management (IGUM) version (5.0) have largely been adopted, with permission, from the [Criteria for the Clinical Use of Immune Globulin](#) (2022 edition) produced by Prairie Collaborative Immune Globulin Utilization Management Framework Project, and with guidance of the Ontario IG advisory panel. There may be new evidence to support IG use in other medical conditions since publication of the Prairie Collaborative document, however this has not been included in version (5.0). New evidence will be considered in the comprehensive review and update to commence in 2026.

Highlights of version 5.0 include:

- ✓ IG prescribing best practice recommendations, with medical condition specific review criteria where appropriate.
- ✓ Consistent use of the adjusted body weight IG dose calculator in all patients meeting height and weight criteria
- ✓ A colour coded categorization of medical conditions, including a **Do Not Use** (n=33) category
- ✓ A visual aid for quick reference of all recommendations where **IG Can be Used** (n=51) is available in the appendix.

Medical Condition changes from version 4.0 to 5.0:

Specialty	Medical Condition in V4.0	Change in V5.0
Dermatology	Pemphigus Vulgaris (PV) and Variants	PV now falls under Autoimmune Blistering Disease. Updated recommendation and dosing.
Hematology	Allogeneic Bone Marrow or stem cell transplantation	<ol style="list-style-type: none"> 1. CMV induced pneumonitis in allogeneic stem cell transplant move from Not for Routine Use → IG Can be Used category. 2. Prevention of GVHD in high-risk allogeneic stem cell transplant move from Not for Routine Use → Do Not Use category.
Immunology	Primary Immune Deficiency (PID)	Updated recommendations and dosing
Immunology	Secondary Immune Deficiency (SID)	Updated recommendations and dosing. Other medical conditions added refer to Hypogammaglobulinemia / SID section providing guidance on conditions that cause hypogammaglobulinemia. (e.g., hematological malignancies)
Infectious Diseases	<ul style="list-style-type: none"> • Staphylococcal Toxic Shock • Invasive Group A streptococcal fasciitis with associate toxic shock 	Both medical conditions fall under Toxic Shock Syndrome. Updated dosing.
Neurology	Acute disseminated Encephalomyelitis (ADEM)	Moved from Not for Routine Use → IG Can be Used category. Updated recommendations and dosing.
Neurology	N-methyl-D- aspartate (NMDA) encephalitis	NMDA now falls under Autoimmune encephalitis mediated by antibodies (AMAE) targeting cell surface antigens. Updated recommendations and dosing.
Neurology	Lambert-Eaton Myasthenic Syndrome (LEMS)	Moved from Not for Routine Use → IG Can be Used category. Updated recommendations and dosing.
Neurology	Stiff Person Syndrome (Moersch – Woltman Syndrome)	Moved from Not for Routine Use → IG Can be Used category. Updated recommendations and dosing.
Transplant	<ul style="list-style-type: none"> • Peri-Transplant (Heart, lung kidney, pancreas) • Post-Transplant 	Peri and Post-Transplant now fall under Solid organ transplant active antibody mediated rejection (ABMR)

		prevention and management. Updated recommendations and dosing.
Transplant	<ul style="list-style-type: none"> • Kidney transplant from living donor to whom the patient is sensitized • Pre-Transplant (heart) 	Kidney living donor and Pre-heart transplant now fall under Solid organ transplant ongoing desensitization, prevention or treatment of graft rejection. Updated recommendations and dosing.

Number of new medical conditions added in the **IG Can be Used category by specialty:**

Specialty	New Medical Condition added in V5.0
Dermatology = 2	<ul style="list-style-type: none"> ▪ Pyoderma gangrenosum ▪ Scleromyxedema
Hematology = 7	<ul style="list-style-type: none"> ▪ Gestational alloimmune neonatal hemochromatosis ▪ Hemolytic disease of the fetus- prevention ▪ Heparin-induced thrombocytopenia ▪ Neonatal hemochromatosis- prevention ▪ Neonatal thrombocytopenia secondary to maternal autoimmune disorders ▪ Vaccine induced immune thrombotic thrombocytopenia / vaccine induced prothrombotic immune thrombocytopenia
Immunology = 0	
Infectious Diseases = 3	<ul style="list-style-type: none"> ▪ Hepatitis A post exposure prophylaxis (Intramuscular information only) ▪ Measles post exposure prophylaxis ▪ Varicella-zoster virus prophylaxis (when VZIG not available)
Neurology = 7	<ul style="list-style-type: none"> ▪ Relapsing remitting multiple sclerosis, short term therapy ▪ Myelin Oligodendrocyte glycoprotein antibody-associated disorders – pediatric ▪ Neuropathy associated with IgM paraproteinemia without anti-MAG antibodies ▪ Opsoclonus-myooclonus ataxia, pediatric onset ▪ Sjögren syndrome associated neuropathy ▪ Sydenham chorea ▪ Vasculitic Neuropathy as part of a systemic disorder
Rheumatology = 5	<ul style="list-style-type: none"> ▪ Antiphospholipid syndrome – catastrophic ▪ Autoimmune retinopathy ▪ Eosinophilic granulomatosis with polyangiitis (Churg-Strauss disease) ▪ Macrophage activation syndrome ▪ Multisystem inflammatory syndrome in children associated with SARS-CoV-2 / COVID-19 infection
Transplant = 2	<ul style="list-style-type: none"> ▪ Community acquired respiratory virus, upper respiratory tract infection in high-risk patients ▪ Parvovirus B19 in solid organ transplant recipients
Other = 1	<ul style="list-style-type: none"> ▪ Systemic capillary leak syndrome